.
EC 2.1.1.354 ([histone H3]-lysine(4) N-trimethyltransferase) inhibitor - Ontology Report - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:EC 2.1.1.354 ([histone H3]-lysine(4) N-trimethyltransferase) inhibitor
go back to main search page
Accession:CHEBI:228263 term browser browse the term
Definition:An EC 2.1.1.* (methyltransferases) inhibitor that interferes with the action of [histone H3]-lysine(4) N-trimethyltransferase (EC 2.1.1.354).
Synonyms:related_synonym: ASH1L inhibitor;   ASH1L inhibitors;   EC 2.1.1.354 ([histone H3]-lysine(4) N-trimethyltransferase) inhibitors;   EC 2.1.1.354 inhibitor;   EC 2.1.1.354 inhibitors;   KMT2H inhibitor;   KMT2H inhibitors;   KMT3C inhibitor;   KMT3C inhibitors;   KMT3D inhibitor;   KMT3D inhibitors;   KMT3E inhibitor;   KMT3E inhibitors;   MLL5 inhibitor;   MLL5 inhibitors;   PRDM9 inhibitor;   PRDM9 inhibitors;   SMYD1 inhibitor;   SMYD1 inhibitors;   SMYD2 inhibitor;   SMYD2 inhibitors;   SMYD3 inhibitor;   SMYD3 inhibitors;   [histone H3]-lysine(4) N-trimethyltransferase inhibitor;   [histone H3]-lysine(4) N-trimethyltransferase inhibitors

 Loading Annotations... 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
X

show annotations for term's descendants           Sort by:
LLY-507 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd36 CD36 molecule multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA CTD PMID:29718165 NCBI chr 4:18,209,088...18,302,142
Ensembl chr 4:17,354,466...17,513,903 		JBrowse link
G Ifng interferon gamma multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MARCO mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MMP9 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MSR1 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of IL6 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of TNF mRNA CTD PMID:29718165 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of IL6 mRNA CTD PMID:29718165 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Marco macrophage receptor with collagenous structure multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MARCO mRNA CTD PMID:29718165 NCBI chr13:34,169,011...34,210,340
Ensembl chr13:31,616,278...31,648,521 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MMP9 mRNA CTD PMID:29718165 NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Msr1 macrophage scavenger receptor 1 multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MSR1 mRNA CTD PMID:29718165 NCBI chr16:59,421,250...59,507,070
Ensembl chr16:52,717,732...52,799,676 		JBrowse link
G Smyd2 SET and MYND domain containing 2 multiple interactions ISO LLY-507 binds to and results in decreased activity of SMYD2 protein CTD PMID:25825497 NCBI chr13:103,956,470...103,997,774
Ensembl chr13:101,425,273...101,466,576 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of TNF mRNA CTD PMID:29718165 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19904
    role 19875
      biological role 19873
        biochemical role 19583
          enzyme inhibitor 18780
            EC 2.* (transferase) inhibitor 14985
              EC 2.1.* (C1-transferase) inhibitor 3779
                EC 2.1.1.* (methyltransferases) inhibitor 691
                  EC 2.1.1.354 ([histone H3]-lysine(4) N-trimethyltransferase) inhibitor 8
                    AZ505 0
                    LLY-507 8
paths to the root